Earnings Call
Apr 21, 2026
Q1 FY2026
EPS Estimate
2.34
EPS Actual
2.50
Post-Earnings Close
$205.04
Earnings Reaction
+4.4%
Quest Diagnostics opened 2026 with its strongest organic growth performance in recent memory, posting 9.2% consolidated revenue growth to $2.9 billion and adjusted EPS of $2.50, well ahead of the $2.34 consensus estimate and up roughly 13% year-over-year. Critically, nearly all of that top-line expansion was organic, driven by a combination of broad-based clinical demand, new customer channel penetration, and two transformative partnerships with Fresenius Medical Care and Corewell Health that together contributed approximately 7 percentage points to organic volume growth. Stripping those two relationships out, underlying organic volume still grew 3.8% and revenue per requisition rose 2.5%, reflecting genuine mix improvement rather than just volume leverage.
Report generated on Apr 21, 2026
AI-generated earnings analysis. Not investment advice.
Chief Executive Officer
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
Read the full DGX analysis
The complete report, with key themes, analyst Q&A summary, notable quotes, and market context — is free with an account. No password, no card.